Anavex Life Sciences Corp (AVXL)

[falconer66a]

Previous, Other Work By Firms Not Applicable

I know that they have worked with numerous companies but how many successes can be attributed to their analysis?

That perspective presumes that all clinical trials involve equivalent and parallel mechanisms of action, disease traits, etc. Nothing of the kind.

The new Anavex 2-73 drug trial will be entirely different from any other. There is nothing to compare it to. New drug, with new, exceptional mechanism of action, against a disease no other drug has succeeded for. All of those other drugs worked at downstream stages of Alzheimer’s, clearance of waste proteins. All have failed. Anavex 2-73 works against upstream disease stages, putting cellular things back together so downstream protein accumulations are suppressed.

And, the new trial will be with new drug approval clinical trial protocols, not used in any previous trials.

Therefore, once again it’s an apples and oranges comparison. The predictive successes (or failures) of the retained data analysis firms simply have no bearing on the selection of favorably-responding participants in the upcoming Phase 3 trial. Simply, will the retained firms be able to pull out Anavex winners from the large population of Alzheimer’s sufferers? The biology being examined strongly suggests they will. Previous work with other drugs, diseases, and old-rule trials has no bearing nor indication.